Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model
Lisa Ferguson-Sells, Nieves Velez de Mendizabal, Baohui Li, David Small, Lisa Ferguson-Sells, Nieves Velez de Mendizabal, Baohui Li, David Small
Abstract
Background: Tadalafil 40 mg once daily is approved for adult patients with pulmonary arterial hypertension (PAH). To investigate and potentially fulfill an unmet need in pediatric patients with PAH, pharmacokinetic (PK) data were explored in a pediatric phase Ib/II study and pooled with prior phase III (pulmonary arterial hypertension and response to tadalafil [PHIRST-1]) adult data to develop the first population PK model for tadalafil in pediatric patients with PAH.
Methods: H6D-MC-LVIG (NCT01484431) was an open-label, multicenter, multiple ascending dose study in pediatric patients with PAH, while PHIRST-1 was a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel design study in adults with PAH who received one of five treatments (tadalafil 2.5, 10, 20, or 40 mg, or placebo orally, once daily). PK data from the studies were pooled to develop a pediatric population PK model for tadalafil that characterized relationships among dose, exposure, and the effects of covariates with an aim to develop a population PK model that could simulate concentration-time profiles and assess exposure-matched dosing strategies in a pediatric PAH population.
Results: In line with the observed data, modeling and simulation demonstrated that the doses studied in the pediatric population produced area under the concentration-time curves (AUCs) within the range of those associated with improved exercise ability in adults with PAH. The analyses included 1430 observations from 305 adult patients (PHIRST-1: 69 males and 236 females, 1102 observations) and 19 pediatric patients (LVIG: 6 males and 13 females, 328 observations) who received tadalafil once daily at different dose levels. The best-fit base model retained an effect of weight on apparent volume of distribution (V/F), fixed to the allometric scaling value of 1, and did not include an effect of weight on apparent clearance (CL/F). Other covariate effects were that bosentan increased CL/F, V/F decreased with decreasing body weight, and bioavailability (F) decreased with increasing dose and decreasing age. The PK model reliably predicted the observed concentrations and overall variability evident from the overlap of the individual observed concentrations with the distributions of simulated concentrations.
Conclusions: A one-compartment model parameterized in terms of F, absorption rate constant, CL/F, and V/F described the data well. The model demonstrated that plasma tadalafil concentrations in pediatric patients aged 2 to < 18 years were similar to those in adults at similar doses, and confirmed that dosing of 40 mg once daily in pediatric patients with a bodyweight ≥ 40 kg, and a dose of 20 mg once daily in patients with a body weight < 40 kg and aged ≥ 2 years are suitable for phase III evaluation.
Trial registration number (date of registration): LVIG: ClinicalTrials.gov identifier: NCT01484431 (2 December 2011). PHIRST-1: ClinicalTrials.gov identifier: NCT00125918 (2 August 2005).
Conflict of interest statement
Lisa Ferguson-Sells and Baohui Li are employees of Eli Lilly and Company and own stocks. David Small and Nieves Velez de Mendizabal are former employees of Eli Lilly and Company. NVM is an employee of Metrum Research Group, Tariffville, CT, USA, and DS is an employee of Karuna Therapeutics, Boston, MA, USA.
© 2021. The Author(s).
Figures
References
- Rich S, Rubin LJ, Abenhail L, et al. Executive summary from the world symposium on primary pulmonary hypertension (Evian, France; September 6–10, 1998) Geneva: World Health Organization; 1998. pp. 1–27.
- Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):40S–47S. doi: 10.1016/j.jacc.2004.02.032.
- Beghetti M. Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs. Eur Respir Rev. 2009;18(111):18–23. doi: 10.1183/09059180.00011109.
- Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903. doi: 10.1161/CIRCULATIONAHA.108.839274.
- Small D, Ferguson-Sells L, Dahdah N, Bonnet D, Landry J, Li B. Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: a multiple ascending-dose study. Br J Clin Pharmacol. 2019;85(10):2302–2309. doi: 10.1111/bcp.14039.
- Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329–332. doi: 10.2165/00003088-199630050-00001.
- Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36. doi: 10.2133/dmpk.24.25.
- Adcirca [prescribing information]. Indianapolis: Eli Lilly and Company; 2009. Available at: .
- Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48(5):610–618. doi: 10.1177/0091270008315315.
- Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009;98(12):4962–4974. doi: 10.1002/jps.21789.
- Beal S, Sheiner LB, Boeckmann A, Bauer RJ, editors. NONMEM 7.3.0 users guides (1989, 2013) Ellicott City: Icon Development Solutions; 2013.
- Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Progr Biomed. 2005;79(3):241–257. doi: 10.1016/j.cmpb.2005.04.005.
- Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22(5):431–445. doi: 10.1007/BF02353864.
- Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Progr Biomed. 2004;75(2):85–94. doi: 10.1016/j.cmpb.2003.11.003.
- Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151. doi: 10.1208/s12248-011-9255-z.
- Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver—evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247(2):625–634. doi: 10.1111/j.1432-1033.1997.00625.x.
- Stevens J, Hines R, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307:573–582. doi: 10.1124/jpet.103.054841.
- Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30(8):883–891. doi: 10.1124/dmd.30.8.883.
- Takahiro R, Nakamura S, Kohno H, et al. Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58–65. doi: 10.1248/bpb.b14-00566.
- Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. J Thorac Dis. 2019;11:S1767–S1781. doi: 10.21037/jtd.2019.09.14.
- Tracleer [prescribing information]. South San Francisco: Actelion Pharmaceuticals US, Inc; 2009. Available at: .
Source: PubMed